A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

by Yunxin Chen, Sathish Kumar Gopalakrishnan, Melissa Ooi, Rehena Sultana, Li Hui Lim, Nicholas Grigoropoulos, Shin Yeu Ong, Mingge Xu, SGHMM1 Investigators, Wee Joo Chng, Yeow Tee Goh, Chandramouli Nagarajan
Published 2021-09-01